RxDoctor Payments Data

Stacy Raviv, MD

Pulmonary Disease · Evanston, ILNPI 1568550499

Payments from drug & device makers

$4,137in general payments, 2019–2025

Across 91 payments — averaging $45.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • Regeneron Healthcare Solutions, Inc.$728
  • Intuitive Surgical$368
  • Boehringer Ingelheim$356
  • Inogen, Inc.$252
  • Genentech USA, Inc.$110
  • plus $239 from 7 others

What the payments were for

  • Consulting fees$1,84145%
  • Travel & lodging$3819%
  • Food & beverage$1,81944%
  • Education$962%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,137 in reported general payments places this provider in the 60th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$93,786
Medicare patients
380
Services billed
894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate34$428,881
Trelegy ElliptaFluticasone/Umeclidin/Vilanter231$190,754
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr160$98,102
TezspireTezepelumab-Ekko20$89,876
Breo ElliptaFluticasone/Vilanterol94$47,734
Dupixent PenDupilumab11$42,908
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$38,641
Spiriva RespimatTiotropium Bromide25$31,931
Stiolto RespimatTiotropium Br/Olodaterol Hcl48$29,493
Pirfenidone21$24,084
Spiriva HandihalerTiotropium Bromide23$23,322
DuleraMometasone/Formoterol42$16,749
SymbicortBudesonide/Formoterol Fumarate37$14,488
Incruse ElliptaUmeclidinium Bromide23$9,510
Advair HfaFluticasone Propion/Salmeterol21$8,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$356$490,305107 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$24$349,479528 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$35$143,005104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Evanston

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →